Remiges Ventures is an institutional investor (Conventional VCs) founded in 2014 and headquartered in Cambridge, United States. Venture capital firm investing in innovative drug discovery and biotechnology companies. The firm focuses on incubating early-stage drug discovery seeds and supporting portfolio companies through clinical trials and strategic collaborations. It actively seeks out companies developing novel therapies and technologies, particularly in areas like retinitis pigmentosa, ALS, and solid tumors. The firm fosters partnerships between its portfolio companies and established entities for research and development. It supports advancements in areas such as gene therapy, single-domain antibody programs, and novel delivery systems for neurodegenerative diseases. The firm plays a role in advancing healthcare solutions and improving patient outcomes through strategic investments and active involvement in the growth of its portfolio companies.

Stage

seed, early-stage venture, Series A, Series B, Series C, seed, early-stage venture, Series A, Series B, Series C

Check size

$5M-$50M

HQ

Cambridge, United States

Founded

2014

Website

https://remigesventures.com

LinkedIn

https://linkedin.com/company/remiges-ventures-inc.

What they look for

Focus on intellectual properties from Japanese academia; global early-stage drug discovery companies; preference for therapeutics with commercial opportunity

Preparing to pitch Remiges Ventures?

CrackTheDeck analyzes your pitch deck before the meeting — structure, narrative, investor fit.